Browse the evidence

GLP-1 receptor agonists have demonstrated cardioprotection in patients with type 2 diabetes and heart failure.

Incorporating GLP-1RAs into treatment plans may improve cardiovascular outcomes in diabetic patients.

Obesity negatively impacts ovarian stimulation and is associated with reproductive disorders.

Addressing obesity may improve fertility treatment outcomes.

Ghrelin concentration significantly reduces post-meal in both moderate and high protein diets.

Both moderate and high protein diets effectively reduce ghrelin levels, indicating a potential for managing hunger.

GLP-1 receptor agonists have shown promising results in reducing liver enzymes and improving MASLD.

Practitioners may consider GLP-1 RAs as a therapeutic option for MASLD.

The long-acting GIPR agonist LY3537021 induced a mean body weight loss of 3.14 kg in participants with T2D compared to 0.36 kg in the placebo group at day 57 (p < 0.05).

LY3537021 may be an effective treatment option for weight loss in patients with T2D.

LY3537021 was well tolerated with infrequent gastrointestinal adverse events.

LY3537021 may be a safe option for patients with T2D.

Retatrutide (LY3437943) is a novel triple agonist that targets GLP-1, GIP, and glucagon receptors, representing a transformative advance in obesity pharmacotherapy.

Retatrutide may be considered as a new treatment option for obesity.

Glucagon-like peptide-1 receptor agonists may encourage a more holistic approach to treatment of CKM syndrome.

Clinicians should consider using GLP-1 receptor agonists for integrated treatment strategies.

The efficacy of GLP-1 receptor agonists was consistent across other important subpopulations.

GLP-1 receptor agonists can be considered effective for weight loss across diverse patient groups.

New treatment approaches, including glucagon-like peptide-1 agonists, may be effective for weight loss in pregnant individuals.

Healthcare providers should consider new medical therapies for managing obesity in pregnant individuals.

Insulin therapy often leads to fat mass accumulation and increases the risk of sarcopenic obesity.

Practitioners should be cautious of insulin therapy's potential to increase fat mass and risk of sarcopenic obesity.

Glucagon-like peptide-1 (GLP-1) receptor agonists are widely prescribed for the treatment of type 2 diabetes and obesity.

Practitioners should consider GLP-1 receptor agonists for managing type 2 diabetes and obesity.

A statistically lower proportion of patients in the compounded Semaglutide group (71.61%) reported at least one side effect compared to the pure Semaglutide group (77.40%).

Practitioners may consider that compounded Semaglutide is associated with a lower incidence of side effects.

The proposed nanocomplex is a promising system for long-acting injectable delivery of semaglutide, potentially enhancing patient compliance.

This delivery system may improve treatment adherence in patients requiring semaglutide.

GLP-1 RA initiation was associated with a reduced incidence rate of alcohol use disorders (AUD) post RYGB (1.1% vs. 1.8%) with a hazard ratio of 0.77.

Practitioners may consider GLP-1 RAs as a strategy to reduce AUD in patients post RYGB.

GLP-1 receptor agonists (GLP-1 RAs) can lead to modest yet statistically significant reductions in systolic blood pressure (SBP).

GLP-1 RAs may be considered as adjunctive therapies for managing hypertension.

Obesity increases the risk of hypertension and other cardiometabolic comorbidities.

Practitioners should be aware of the increased risk of hypertension in obese patients.

The evolution of anti-obesity pharmacotherapy has progressed to modern gut hormone-based therapies, notably glucagon-like peptide-1 receptor agonists (GLP-1RAs), which effectively suppress appetite and improve glycemic control.

Practitioners should consider GLP-1RAs as effective options for appetite control and glycemic management in obesity treatment.

HbA1c decreased from 5.5 ± 0.3 at baseline to 5.3 ± 0.3 at 12 weeks and to 5.2 ± 0.027 at 24 weeks.

Practitioners can expect improvements in glycemic control in patients using compounded GLP-1 ± GIP agonists.

Multiple incretin pharmaceutical agents show promise in the prevention and treatment of T2D.

Stay informed about new incretin agents for T2D prevention and treatment.

High sodium intake above 4,000 mg/d leads to a linear increase in mean arterial pressure (MAP).

Practitioners should be aware that high sodium intake can significantly affect blood pressure.

Sodium intake below 1,200 mg/d cannot maintain homeostasis.

Practitioners should recognize that insufficient sodium intake can lead to physiological imbalances.

Abdominoplasty following GLP-1 RA-induced massive weight loss shows a trend toward a lower overall complication rate (20% vs 40%) compared to postbariatric surgery.

Practitioners may consider GLP-1 RA therapy as a safer option for patients seeking abdominoplasty after significant weight loss.

Leptin levels significantly decline following semaglutide treatment, particularly in the obesity group (-5.10 ng/mL).

Semaglutide may help lower leptin levels, which could be beneficial for weight management in diabetic patients.